The IPO proceeds will fund expansion of manufacturing capacity, commercial infrastructure, and R&D for new assays and the ARGO HT/DX diagnostic instrument. Monitor for execution on these growth initiatives and potential follow-on offerings.
Executive Summary
Alamar Biosciences has priced its IPO of 11.25 million shares at $17.00 per share, raising $177.9 million in net proceeds. This follows a strong growth trajectory with 196% YoY revenue growth in 2025, driven by its ARGO HT System adoption and consumable pull-through. The offering is immediately dilutive to new investors.
Key Financial Metrics
Key Facts
- IPO priced at $17.00 per share for 11,250,000 shares
- Raised $191.25 million in gross proceeds
- Net proceeds to company are $177.9 million after underwriting fees
- Underwriters granted option to purchase up to 1,687,500 additional shares
- 2025 revenue was $74.2 million, up 195% from $25.1 million in 2024
- Gross margin improved to 56% in 2025 from 34% in 2024
- Company has an accumulated deficit of $168.8 million as of December 31, 2025
Financial Impact
Raised $177.9 million in net proceeds from the IPO
Risk Factors
- Continuing net losses and negative cash flows from operations
- Dependence on single-source suppliers for critical components
- Significant competition from established players like Olink and Quanterix
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-161647 |
| Document: 0001193125-26-161647-index-headers.html | 0001193125-26-161647 |
| Document: 0001193125-26-161647-index.html | 0001193125-26-161647 |
| Document: 0001193125-26-161647.txt | 0001193125-26-161647 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (−11.93%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (−11.93%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.69 (+11.93%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.69 (−4.87%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.69 (−6.43%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.69 (+0.66%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.69 (−16.08%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.69 (+12.01%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.69 (+7.99%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.69 (+28.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers